Streetbeat News

Revenues

BROS

Thirteen analysts have provided mixed ratings for Dutch Bros (NYSE:BROS) over the past quarter. The average 12-month price target is $42.62, with a high of $50.00 and a low of $31.00. Recent analyst actions include both upgrades and downgrades, reflecting varied sentiment. Despite strong revenue growth, Dutch Bros faces challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 12:00 pm

GFAI

Guardforce AI has announced that it anticipates a new revenue stream across all its operating areas, which could positively impact its financial performance.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 12:00 pm

JD

JD.com (NASDAQ: JD) reported Q2 2024 revenue growth of 1.2% YoY to $40.098 billion, beating analyst estimates. Adjusted net income per ADS was $1.29, surpassing the $0.83 estimate. The stock price rose 4.17% in premarket trading. JD Retail and Logistics segments showed gains, while new business revenues fell. Operating margin improved to 3.6%, and free cash flow was $6.82 billion.

Portfolio Pulse from Anusuya Lahiri

August 15, 2024 | 11:59 am

WMT

Walmart Inc (NYSE:WMT) reported strong Q2 2025 earnings, with adjusted EPS of $0.67 beating the consensus of $0.64 and sales of $169.34 billion surpassing the expected $168.57 billion. The company raised its full-year guidance and saw significant growth in its eCommerce and advertising businesses. Walmart's shares are trading higher following the announcement.

Portfolio Pulse from Lekha Gupta

August 15, 2024 | 11:47 am

GOOGL

META

MSFT

Mark Zuckerberg discussed how Meta Platforms Inc. (NASDAQ:META) succeeded over tech giants like Google, Microsoft, and Yahoo in the social networking space. He attributed Meta's success to its agility and conviction in new ideas, contrasting it with the slower, more skeptical approach of larger companies. Meta's acquisitions of Instagram and WhatsApp further solidified its dominance.

Portfolio Pulse from Rounak Jain

August 15, 2024 | 11:44 am

SLN

Silence Therapeutics reported a Q2 EPS of (11.10) pence, down from (9.60) pence year-over-year. Sales decreased significantly to £598.00K from £9.10M YoY. The company holds cash, cash equivalents, and U.S. Treasury bills totaling £149.6M (~$189.2M).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:42 am

CVAC

CureVac reported Q2 sales of €14.400 million, which may not be comparable to the €5.441 million estimate. The company also reported a pre-tax loss of €71.2 million.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:36 am

BLRX

As of June 30, 2024, BioLineRx had $40.1 million in cash, cash equivalents, and short-term bank deposits, which is expected to be sufficient to fund operations into 2025.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:29 am

CSCO

GOOGL

LITE

NKE

QQQ

SPY

WMT

U.S. stocks are poised for a modestly higher start, with the S&P 500 aiming for a sixth consecutive win. Key data on job market, consumer spending, and manufacturing activity, along with retail earnings, will influence trading. Walmart's strong earnings and guidance boost shares, while Alphabet faces potential DOJ action. Cisco and Lumentum see premarket gains on positive earnings. Upcoming economic data and Fed speeches will be closely watched.

Portfolio Pulse from Shanthi Rexaline

August 15, 2024 | 11:29 am

CLBT

Cellebrite has increased its 2024 revenue outlook from $370M-$380M to $390M-$398M, surpassing the estimated $378.306M. The company also projects Q3 revenue of $100M-$104M, exceeding the estimated $94.77M.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:26 am